Feng Xue, MD

Chief physician
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China
Tianjin, Tianjin, China (People's Republic)

Dr. Feng Xue is now a Chief physician at Thrombosis& Hemostasis Center，Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College.
The representative achievement in hemophilia area includes accomplishing the first liver targeted, AAV mediated gene therapy for hemophilia B in China. Serve as Deputy leader of thrombosis and Hemostasis Group, Chinese Society of Hematology, .Deputy Secretary General of Hemophilia Group of China Alliance for Rare Disease.

Presentation(s):

• PB0242 - A phase I tiral evaluating safety and pharmacokinetics in human and an ex vivo pharmacodynamics study in hemophilia patients of KN057, the first anti–TFPI monoclonal antibody in China

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0212 - Evaluation of Omfiloctocog alfa (SCT800) Efficacy in Real-World Treatment of Severe Hemophilia A in China: Insights from the SURPASS Study

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0271 - Health Literacy of People with Haemophilia in China – Results of a Cross-sectional, Community-Based Survey

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0265 - Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicenter real-world study in China

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 21.5 - An Open-label,Dose-Escalation,Multicenter Phase I Study to Evaluate the Safety,Immunogenicity,and Pharmacokinetics/pharmacodynamics（PK/PD）of Single Dose SS109 in Hemophilia A/B patients with Inhibitor

  Sunday, June 23, 2024
  15:45 – 16:00 ICT

• OC 30.4 - Sustained efficacy of gene transfer with BBM-H901 in Chinese Hemophilia B patients: results of long term follow up

  Monday, June 24, 2024
  10:15 – 10:30 ICT

• PB0691 - Kabuki syndrome complicated by severe immune thrombocytopenia and autoimmune thyroiditis: identification of a novel pathogenic mutation

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 40.1 - A Novel Extended half-life factor VIII Fc fusion protein FRSW107 for severe hemophilia A: A multicentre, open-label, single-arm, phase 3 study and its open-label extension

  Monday, June 24, 2024
  14:45 – 15:00 ICT

• Gene therapy for Haemophilia in Asia Pacific

  Tuesday, June 25, 2024
  12:33 – 12:45 ICT

• Panel Discussion

  Tuesday, June 25, 2024
  12:45 – 13:00 ICT